Beyond Air Inc

NASDAQ:XAIR   3:59:50 PM EDT
10.19
-0.25 (-2.40%)
Products

Beyond Air’S Lungfit® PH Receives FDA Approval To Treat Term And Near-Term Neonates With Hypoxic Respiratory Failure

Published: 06/28/2022 20:52 GMT
Beyond Air Inc (XAIR) - Beyond Air’s Lungfit® Ph Receives FDA Approval to Treat Term and Near-term Neonates With Hypoxic Respiratory Failure.
Beyond Air Inc - Beyond Air Commercial Team Will Be Actively Working With Select Hospitals Beginning This Month to Make Lungfit Ph Available.
Beyond Air Inc - Broader U.S. Hospital Launch Expected in First Half of 2023.